Condoliase
| Clinical data | |
|---|---|
| Trade names | Hernicore |
| Other names | Chondroitinase ABC; SI-6603 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| ECHA InfoCard | 100.029.785 |
| Chemical and physical data | |
| Formula | C5039H7770N1360O1525S22 |
| Molar mass | 112508.90 g·mol−1 |
Condoliase (Hernicore) is a biopharmaceutical for the treatment of lumbar disc herniation. Clinical trials have shown its benefit in alleviation of lumbar disc herniation associated low back pain and disability, although some concerns have been suggested with regard to promotion of disc degeneration.[1][2]
Condoliase is derived from the enzyme mucopolysaccharidase from the Gram-negative bacteria Proteus vulgaris.[3][4] It functions as an enzymatic chemonucleolysis product, specifically designed to reduce the size of the protruded herniation.[5] It is an enzyme that specifically degrades glycosaminoglycans.[6][7][4]
It was approved for use in Japan in 2018 as a treatment for lumbar disc herniation.[8]
References
[edit]- ^ Oshita Y, Matsuyama D, Sakai D, Schol J, Shirasawa E, Emori H, et al. (September 2022). "Multicenter Retrospective Analysis of Intradiscal Condoliase Injection Therapy for Lumbar Disc Herniation". Medicina. 58 (9): 1284. doi:10.3390/medicina58091284. PMC 9501482. PMID 36143959.
- ^ Kobayashi K, Sato K, Ando T, Ando K (March 2023). "MRI characteristics of disc degeneration after condoliase injection in young patients: A consecutive case series". Journal of Orthopaedic Science. 29 (2): 494–501. doi:10.1016/j.jos.2023.02.013. PMID 36872214.
- ^ Watanabe I, Shirogane T, Matsuyama Y, Chiba K (September 2022). "Effect of contrast media on the enzyme activity of condoliase: In vitro assessment". JOR Spine. 5 (3): e1221. doi:10.1002/jsp2.1221. PMC 9520762. PMID 36203868.
- ^ a b Chiba K, Matsuyama Y, Seo T, Toyama Y (August 2018). "Condoliase for the Treatment of Lumbar Disc Herniation: A Randomized Controlled Trial". Spine. 43 (15): E869–E876. doi:10.1097/BRS.0000000000002528. PMID 29257028. S2CID 24111394.
- ^ Schol J, Ambrosio L, Tamagawa S, Joyce K, Ruiz-Fernández C, Nomura A, et al. (June 2024). "Enzymatic chemonucleolysis for lumbar disc herniation-an assessment of historical and contemporary efficacy and safety: a systematic review and meta-analysis". Scientific Reports. 14 (1): 12846. Bibcode:2024NatSR..1412846S. doi:10.1038/s41598-024-62792-8. PMC 11150519. PMID 38834631.
- ^ Chiba K, Matsuyama Y, Toyama Y (2014). "Efficacy and Safety of Condoliase in Patients with Lumbar Disc Herniation: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial". The Spine Journal. 14 (11): S30. doi:10.1016/j.spinee.2014.08.081.
- ^ Matsuyama Y, Chiba K, Iwata H, Seo T, Toyama Y (May 2018). "A multicenter, randomized, double-blind, dose-finding study of condoliase in patients with lumbar disc herniation". Journal of Neurosurgery. Spine. 28 (5): 499–511. doi:10.3171/2017.7.SPINE161327. PMID 29424676.
- ^ "Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation". Seikagaku Corp (Press release). 23 March 2018 – via Reuters.